ReviewFrontiers in physiology2026
Metabolic reprogramming in hepatic stellate cells: unveiling a novel therapeutic target for liver fibrosis.
Review in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver fibrosis represents a pathological reparative process for the liver that occurs due to persistent harm, closely linked to sustained liver damage and inflammation. In healthy livers, hepatic stellate cells remain quiescent; however, following liver injury, their transformation into myofibroblasts results in extracellular matrix deposition, thereby worsening the developing stages of hepatic fibrosis. According to research, the main cause of liver fibrosis is the activation of hepatic stellate cells. Significant progress has been made in the study of the development and regression mechanisms of liver fibrosis in recent years, as well as a better understanding of the function of hepatic stellate cells in the fibrous process. The metabolic reprogramming of hepatic stellate cells is a crucial factor facilitating their activation and is essential for their effector roles and anabolic requirements; current research indicates that mechanosignaling is a significant regulator of cellular metabolism. This study summarizes the impact of hepatic stellate cell energy metabolism on fibrosis progression, examines the relationship between mechanomechanics and cellular metabolism, and discusses the therapeutic possibility of targeting cellular energy metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.